Modern regenerative medicine research has expanded well past the development of traditional drugs and medical devices with many promising new therapies encompassing an increasingly diverse range of substances, notably cell-based therapies. These substantial recent developments and the progress in the health care and therapeutics fields necessitate a new regulatory framework agile enough to accommodate these unique therapies and acknowledge their differences with traditional pharmaceuticals. In the United States, recent proposed changes in the regulatory framework for autologous human cells, tissues, and cellular and tissue-based products (HCT/Ps) and their perceived risk-benefit analysis for patients remain controversial in the scientific field.
In the United States, original attempts by the Food and Drug Administration (FDA) -Second tier (middle risk): Also referred to as "361 HCT/P products" after Section 361 of the PHS Act, which governs their use.
Eligible products (a) must be minimally manipulated for (b) homologous use (as determined by advertising and labelling of product), (c) cannot be combined with "another article, except for water, crystalloids, or a sterilizing, preserving, or storage agent" (these Most would consider this patchwork system to be inefficient in accommodating the inherent differences between traditional pharmaceuticals and cell-based products. However, between 2001 and the enactment of the 21st Century Cures Act, the FDA made minimal changes to these regulations, with most changes even further limiting the cell types eligible for the pathways available within the existing lower risk tiers.
As a result of the slow-to-change FDA, patients turned both to stem cell tourism, pursuing cell therapy treatments in countries with less regulation, and to the, as of 2016, 570 domestic clinics selling unapproved stem cell therapies that have sprouted up across the United States (Turner & Knoepfler, 2016) . Recently, there has been much media attention given to the deregulation of stem cell therapies in Texas through a recent law that allows for patients to access unapproved stem cell products if a physician approves and oversees the treatment (Servick, 2017) . In early August 2017, the U.S. Senate unanimously voted to pass a "Right to Try" bill, which gives terminally ill patients access to experimental therapies that have not yet been approved by the FDA (Pear & Kaplanug, 2017) . This bill that has been part of a lager movement that has resulted in the rapid adoption of similar "Right to Try" legislation by 38 of the 50 U.S. states as of October 2017 (Goldwater Institute, 2017) . Although this bill still requires ratification by Congress, the current political climate in the United States appears to be ripe for a bill supporting further deregulation of the federal government to pass. If passed, this bill could be the first to restrict the FDA's current control over the regulation of cell therapies (FDA, 2017d) .
Given this political context, this article will focus on providing an overview of the regulatory momentum that has been gathering over the past 5 years in the United States to specifically reframe the translation policies for HCT/Ps. This review will outline the four draft guidance documents released by the FDA before the enactment of the 
| FOUR DRAFT GUIDANCE DOCUMENTS FRAMING FDA PERSPECTIVES ON HCT/Ps
Draft guidance documents outline the FDA's current definition and recommendations on certain topics within their jurisdiction. They are not official regulations unless they are officially adopted, but they provide useful insight into the FDA's perspective on certain controversial topics and can serve as a litmus test for organizations applying for certain FDA-warranted approvals. The FDA usually disseminates such documents in part to provide advice and recommendations to the relevant establishments and organizations that may need to apply for product approval, but also to collect feedback and commentary from the pertinent stakeholders on the topics before finalizing the document. The four criteria necessary for products to qualify for the second tier within the FDA's HCT/P regulatory hierarchy have been the focus of much of the regulatory debate related to cell therapies. In particular, most of the recent debate has been centred around clarifying the FDA's definitions of "homologous use" and "minimal manipulation," two requirements relevant to "the 361 HCT/Ps" that fall under this second tier and are exempt from FDA premarketing regulation.
Between 2014 and 2015, four controversial FDA draft guidance documents were released, further narrowing the Administration's definitions of these terms: As part of the intent behind draft guidance documents is to collect feedback from the relevant stakeholders before finalization, and because the content of these draft guidance documents was controversially narrowing definitions of some FDA preapproval exclusion criteria, the FDA was urged to hold public hearings to discuss the draft guidance documents' content. Due to considerable public interest, the original hearing was converted to a 2-day public hearing and postponed from April 13, 2016, to September 12 and allow stakeholders additional time to prepare (FDA, 2016c (FDA, , 2016d .
A total of 76 speakers, including patients and stakeholders from industry, academia, and private consultancies, participated in the public hearing (FDA, 2016g, 2016e) . Table 1 outlines the titles of the current four FDA draft guidance documents pertaining to cell therapy-related topics, their main points for consideration, and the reference information in the Federal Register. In the subsequent subsections, we expand on the key details within these draft guidance documents. In this draft guidance, the FDA narrowly defines the "same surgical procedure exception" for HCT/P uses that would fall outside of FDA regulation. In order for the surgical exception to apply, three criteria must be met: (a) HCT/Ps must be removed from and implanted into the same patient, (b) the surgical removal and implantation must occur within the same procedure, and (c) HCT/Ps must remain "in their original form," so that the "communicable disease risks" would remain the same as those usually associated with surgery (FDA, 2014c) . Eligible procedures were narrowly defined to involve HCT/P removal and implantation back into the same patient within a single operation performed at the same establishment. Rinsing or cleaning, labelling, and temporary storage of HCT/P were the only cell processing steps allowed within what could be considered the same surgical procedure exception.
"Autologous use" is the term given to describe the first criteria for surgical exception and is further defined in this draft guidance to include "the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual from whom these cells or tissue were originally removed" (FDA, 2014c) . Although this guidance presents additional criteria for exemption from FDA preapproval in addition to those outlined in the first and second tiers, interestingly, this guidance limits eligible procedures to include only those that occur within the same patient, whereas the earlier 361 product criteria viewed autologous use to be the same level of risk as allogeneic use in a close relative. This guidance was finalized with the same title in November 2017 (FDA, 2017n (FDA, 2014b) In this draft guidance, the FDA provide further definition of minimal manipulation expanding on the original description given in 21 CFR Part 1271 and providing numerous examples of procedures that qualify as minimal manipulation or would otherwise be considered more than minimal manipulation (FDA, 2014b) . As in the original regulation, the definition for minimal manipulation is divided into two sections within this guidance depending on whether the relevant cells/tissues are classified as structural tissues or are considered cells/nonstructural tissues. Structural tissues are defined as those that serve as a barrier or provide support within the body, such as bone, skin, blood vessels, or adipose tissue. Nonstructural tissues are defined to "serve predominantly metabolic or other biochemical roles in the body, such as hematopoietic, immune, and endocrine functions" and include tissues such as cord blood, bone marrow aspirate, lymph nodes, and pancreatic tissue (FDA, 2014b) .
Minimal manipulation for structural tissues was originally defined as processing that does not alter the "original relevant characteristics sion into the heart to prevent tissue remodelling after a heart attack would be nonhomologous use. Both structural and cellular/nonstructural HCT/P can perform homologous uses even if they are acting in locations within the recipient's body that differ from where they act in the donor. For example, implanting a dermal graft to cover and protect a tendon would be a homologous use of the dermis; however, use of the same dermal product to replace or repair a tendon would be nonhomologous uses.
In a recent profile on unapproved cell therapy clinics, some businesses were found to advertise their stem cell therapies as treatments for over 30 diseases, most of which could not possibly qualify as homologous use under the definitions outlined in this draft guidance (Turner & Knoepfler, 2016) . Concerningly, the sixth most common cell type marketed by these clinics was categorized "undefined" in this analysis (Turner & Knoepfler, 2016) , which would pose complications given that the FDA specifies homologous use of products is determined by product "labeling, advertising, or other indications of manufacturer's objective intent" (Munos, 2009) . Further, some clinics would interchange terms such as "placental stem cells"
and "amniotic stem cells," making the true source of such clinics' cells unclear (Turner & Knoepfler, 2016) .
The content of this draft guidance was finalized in the recent guidance document on minimal manipulation and homologous use (FDA, 2017n) . The recent final guidance explicitly highlights that any HCT/P used "for a myriad of diseases or conditions" is unlikely to be implemented homogenously (FDA, 2017n) . Given this context and the recent legislation in Texas legalizing patient access to unapproved cell therapies as long as they are physician-overseen (Servick, 2017) ,
there is an apparent discrepancy between the federal regulatory policy and some states' policies in enforcing how cell therapies progress and are regulated within this rapidly growing, unregulated industry. The evolution and potential future judicial resolution of this seeming discrepancy in jurisdiction will be interesting to observe. Table 2 shows detailed information on the contents of the proposed REGROW Act (Coffman et al., 2016; Kirk et al., 2016) . The most substantial changes proposed within the bill were motivated by the changes recommended in the BPC Report and were related to the approval process for cellular therapies and the classification of cellular therapeutics (BPC, 2015) . The Act proposed the creation of a 5-year conditional use period for cellular or tissue therapeutics demonstrating sufficient safety and efficacy, without Phase III investigation (Coffman et al., 2016; Kirk et al., 2016) . To be approved under this proposed conditional approval system, the eligible products are adult human cells and tissues that have been either minimally manipulated for nonhomologous use or more than minimally manipulated products for homologous or nonhomologous use but "do not provoke a significant unintended immune response in the recipient" (Coffman et al., 2016; Kirk et al., 2016) . The adult cells and tissue must be used for "a specific indication" and should "achieve or restore, the same, or similar, function in the recipient as the donor" (Coffman et al., 2016; Kirk et al., 2016) . Within 5 years of conditional approval, an annual report and adverse event reports would need to be submitted to the FDA before and in addition to "an application for approval of a biological product" under the new legislation (Coffman et al., 2016; Kirk et al., 2016) . During the conditional approval period, doctors must inform each patient of the products' conditional approval status.
The expedited approval pathway presented in the REGROW Act would have not only accelerated approval for a broader group of eligible regenerative medicine therapeutics, rather than just for those addressing serious or life-threatening illnesses, as under the existing guidelines, it also would have enabled these products to enter the market before traditional Phase III testing. Critics of this proposed legislation urged that the appropriate existing expedited pathways already existed and warned that circumventing Phase III trials would expose patients to ineffective and potentially harmful products (Turner & Knoepfler, 2016) . The attrition rate for prospective drugs and therapeutics can be as high as 40% in Phase III testing due to concerns over safety or inefficacy (Servick, 2017) . Further, Phase III trials often provide large-scale patient data comparing the current standard of care with the experimental therapy and can provide physicians with important data for instructing and recommending patient use. Critics argued that the financial burden for covering the equivalent of Phase III trial costs for potentially ineffective treatments would be redistributed from commercial entities to the government, patients, private health care, and insurance companies (Editorial, 2016) .
Supporters of the REGROW Act insisted that the traditional clinical trial process was too arduous, time-consuming, costly, and likely prevented perfectly safe and effective treatments from reaching patients in critical need (BPC, 2015) . The amount of time it takes to get potential drugs and therapies from patenting to commercialization has increased over the years with average estimates now well over a decade (Pammolli, Magazzini, & Riccaboni, 2011) . The costs of taking a product through the entire development process has also exponentially increased over the past decades, and now total costs are approximately $2 billion to take a product to the market (Munos, 2009 ). (1) Are "adult human cells or tissues"
Supporters of the REGROW
(2) Examination of immunogenicity reveals no "significant unintended immune response" (3) Are (A) "minimally manipulated for a non-homologous use" or (B) "more-than-minimally manipulated for a homologous or non-homologous use, but are not genetically modified" (4) Are "produced for a specific indication"
(5) Perform "the same, or similar, function in the recipient as in the donor" (6) A biological product approval application (described under PHS Act Section 351(a)) is submitted within 5 years (7) "Annual reports and adverse event reports" should be submitted throughout the conditional approval period until the biological product (8) Approval application is approved (9) Submitted a sponsor application to treat patients within the 5-year conditional use period (10) The product has not been previously conditionally approved for the same use (11) Informed use: Patients must be notified of the conditional approval status of the product and that it has not been proven efficacious.
(12) Stem cell banking: "Public and private cord blood banks, tissue banks, and bone marrow repositories shall be in full compliance with good tissue practice requirements" under 21 CFR 1271.
Section 3. Devices used in recovery, processing, and delivery of cellular therapeutics (a) Clearance-Outlines editing changes to be made to Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FFDC Act).
(b) Clearance or approval of cellular therapeutics.
• Sec. 515B. Classification of cellular therapeutics
• Cellular therapeutic device clearance or approval will depend on in vitro testing performance.
• Classifications of devices "used for cell therapy," should be determined by their general uses: "harvesting, delivery, or processing cells and sustaining the viability and function of the cells in vivo."
• No additional clearance required for approved devices to be used with cells unless they impact the intended use of the device.
• Reclassification of low risk class III products and those lacking previous approval without cells are governed by the FFDC Act.
(c) Combination products-Outlines editing changes to be made to Section 503 of the FFDC Act.
Section 4. Guidance: Amended regulations (a) Guidance-A draft guidance may be released to clarify any of the presented changes within 1 year of enactment, and a final guidance will be issued within 180 days from the end of the comment period.
(b) Amended regulation.
1 In general-Any amendments to 21 CFR to clarify the presented changes should be completed within 1 year of the enactment.
2 Procedure-Outline of amendment process.
(c) Public meeting-Within 90 days of enactment, at least one public meeting will be held to discuss the regulation of HCT/Ps. (Table 3; FDA, 1997a FDA, , 1997b FDA, , 1998 FDA, , 2001a FDA, , 2001b FDA, , 2001d FDA, , 2007 FDA, , 2010 FDA, , 2011a FDA, , 2011b FDA, , 2012a FDA, , 2012b FDA, , 2012c FDA, , 2012d FDA, , 2013a FDA, , 2013b FDA, , 2015b FDA, , 2016a FDA, , 2016b FDA, , 2016e, 2016f, 2017a . Before 2005, most products were aimed at wound healing applications (Yano et al., 2015; Yano, Tsuyuki, Watanabe, Kasanuki, & Yamato, 2013) .
After 2005, the products now target a broader range of applications, including some of the most life-threatening diseases, such as heart disease or cancer. The low number of these approved 351 products is reflective of the lengthy and costly regulation that these HCT/Ps were forced to follow in order to obtain FDA approval. These changes attempted to counteract FDA action by reducing the number of products that would fall under the FDA jurisdiction through redefinition of the product regulatory categorizations and reduction of necessary clinical trial evidence before product release onto the market.
Many of these modifications resembled the conditional and time-limited authorization for RMPs in Japan. The concept of creating an expedited approval pathway for certain therapies was not new. "Accelerated approval" pathways for drugs and biologics for serious or life-threatening illnesses already exist in the United States (Yano, Watanabe, & Yamato, 2016) . "Conditional market authorization" of drugs for serious and life-threatening diseases, emergency situations, and orphan diseases as well as "market authorization under exceptional circumstance" of drugs also exist in the European Union (Yano et al., 2016) . In 2014, Japan became the first country to introduce an expedited approval system that would create a conditional approval pathway for RMPs in the "Pharmaceuticals, Medical Devices and Other Therapeutic Products (PMDA) Act" (Hara, Sato, & Sahara, 2014) . Under the new Japanese system, RMPs, regardless of whether they treat life-threatening diseases, can enter the market after confirming safety and demonstrating efficacy. However, clinical efficacy in large-scale clinical trials must be demonstrated and submitted to the relevant authorities after 7 years.
This Japanese legislation was the initial spark for much of this controversial discussion about regulation of cell therapies amongst the international scientific community (Hara et al., 2014; Konomi, Tobita, Kimura, & Sato, 2015) . Critics of the newly implemented conditional and time-limited authorization system for RMPs in Japan raised concerns that these changes may be too lax and may "flood" the Japanese market with ineffective therapies (Editorial, 2015) . Although it will take years before the impact of the recent changes in the Japanese system are fully understood, the first RMP, HeartSheet®, was already approved RMAT alternative expedited approval pathways will make it challenging to gauge how the FDA's perspective on RMP development and approval will change in the future. Further, unlike the standardized safety criteria laid out for evaluating cell therapy safety and risk in the BPC Report, the case-by-case evaluation will obscure the evaluation process from anyone outside of the FDA, making it difficult to ensure that evaluation is consistent across candidate therapies.
Under the previous U.S. regulations, it would be hard to imagine applications of cell-based therapies that would fulfil the requirements for minimal manipulation and homologous use in such serious diseases as heart disease, seemingly condemning products seeking FDA approval to a longer, more expensive regulatory pathway. Thus it is not surprising that the United States was considered to have the highest density of "stem cell tourism" clinics in the world in 2014 ( Tay implemented "for a myriad of diseases or conditions" are unlikely compatible with the criteria of homologous use required for HCT/Ps to qualify as 361 products. This guidance also lays out a warning that products presenting a higher risk based on their "site of administration" and those implemented for "non-homologous use, particularly those intended to be used for the prevention or treatment of serious and/or life-threatening diseases and conditions" will be the first to be targeted by FDA compliance enforcement. With exception of the most nefarious clinics, which are currently FDA scrutiny, manufactures have been given 3 years to come into compliance, but this premeditated description of products that will be subject to regulation make the FDA's intentions clear, and only time will tell if the Agency has the necessary infrastructure to broadly enforce compliance.
The recent action by the FDA warning several cell therapy clinics that they need to acquire FDA approval in order to sell some of their products shows that the Agency certainly has an interest in attempting to enforce its authority.
The original draft guidance on adipose tissue-derived products The power balance between the U.S. federal and state governments is complex, and ultimate changes to this distribution of power can only the settled through the slow justice of the judicial branch.
Although the REGROW Act died in the previous Congress (GovTrack US, 2017) , some believe that a bill with similar more detailed regulation of the HCT/P therapeutic approval process can be anticipated to reappear in the future, as there is still much room for optimization in the translation of bench-top discoveries to bedside therapies within the existing U.S. system. Through the recent release of several draft guidance documents (FDA, 2017b and warnings to stem cell clinics (FDA, 2017h, 2017i) , the FDA has been taking steps to exert its authority. At the same time, in the wake of the REGROW Act (Coffman et al., 2016) , the gathering momentum of the "Right to Try" movement (Goldwater Institute, 2017; Pear & Kaplanug, 2017; Servick, 2017) , and the current deregulatory political environment in the United
States, there appears to be legislative momentum that could begin to create legal avenues by which the FDA could be side-stepped and the diplomatic provisions of the 21st Century Cures Act could become a thing of the past.
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